BeiGene

BeiGene is a global oncology company developing and delivering cancer treatments across hematology and solid tumors; the company describes itself as building that business under the name BeOne Medicines. Its research spans oncology drug development, clinical research and clinical trials, with particular work in protein degradation (CDACs) and antibody drug conjugates alongside a broad pipeline of earlier and later-stage programmes.

The company employs approximately 12,000 people, of whom more than 1,200 work in research. It has initiated over 175 clinical trials globally and enrolled more than 30,000 patients, running studies in over 45 countries and regions. Three internally developed medicines have gained regulatory approval in more than 75 countries.

BeiGene operates on six continents with more than 45 office locations, combining global reach with local expertise. It is publicly traded on the NASDAQ, HKEX and SSE exchanges. Stated core values are Patients First, Driving Excellence, Bold Ingenuity and Collaborative Spirit, and the company describes its working culture as non-hierarchical, oriented towards scientific excellence and speed, and willing to challenge the status quo.